P/B
2,8
STERIS
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
$20.4B
Market Cap • 9/25/2026
2014
(12 years)
Founded
1992
(34 years ago)
IPO
NYSE
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
3,4
P/EBITDA
12,5
P/OCF
15,8
P/FCF
22
P/E
25,5
BVPS
73,2
EPS
8,2
Market Cap
Market Cap
20,4B
EV
21,9B
EV/Revenue
3,6
EV/EBITDA
13,4
EV/EBIT
19,2
Payout
Dividend Per Share
2,5
Dividend Yield
1,2%
Buyback Yield
1,5%
Total Yield
2,8%
Dividend Yield 5Y
0,7%
Payout
30,7%
Retained Earnings
3,2B
Profitability
Gross Margin
44,4%
EBITDA Margin
27%
EBIT Margin
18,9%
Net Margin
13,4%
D&A/EBITDA
0%
R&D/Revenue
1,9%
Capex/Revenue
6%
Capex/D&A
73,9%
Capex/OCF
28,2%
SBC/OCF
4,9%
% PPE
21,6%
% Goodwill
39%
ROE
11,4%
ROIC
9,2%
Growth
CAGR Revenue 5Y
12,1%
CAGR Op. Income 5Y
20,6%
CAGR Net Income 5Y
23,1%
CAGR EPS 5Y
19,6%
CAGR OCF 5Y
14,6%
Leverage
N.D./EBITDA
1
Debt/Equity
0%
Current Ratio
1,9
Quick Ratio
1,2
Interest Coverage
1880,7%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!